Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901.
Taskar PS, Patil A, Lakhani P, Ashour E, Gul W, ElSohly MA, et al. Δ9-Tetrahydrocannabinol derivative-loaded nanoformulation lowers intraocular pressure in normotensive rabbits. Transl Vis Sci Technol. 2019;8:15–15.
Parihar JKS. Glaucoma: the ‘Black hole’ of irreversible blindness. Med J Armed Forces India. 2016;72:3–4.
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–34.
Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52–9.
Braunger BM, Fuchshofer R, Tamm ER. The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment. Eur J Pharm Biopharm. 2015;95:173–81.
Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121:2081–90.
Glaucoma Summary Benchmarks - 2018 [Internet]. AAO; 2017 Nov p. 6. Available from: https://www.aao.org/summary-benchmark-detail/glaucoma-summary-benchmarks-2018
Glaucoma - Diagnosis and treatment - Mayo Clinic [Internet]. [cited 2019 Oct 15]. Available from: https://www.mayoclinic.org/diseases-conditions/glaucoma/diagnosis-treatment/drc-20372846
Adelli GR, Bhagav P, Taskar P, Hingorani T, Pettaway S, Gul W, et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci. 2017;58:2167–79.
Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol. 1998;116:1433–7.
Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56:2097–102.
Hepler RS, Frank IM, Ungerleider JT. Pupillary constriction after marijuana smoking. Am J Ophthalmol. 1972;74:1185–90.
Marijuana and Medicine: Assessing the Science Base [Internet]. Washington, D.C.: National Academies Press; 1999 [cited 2020 Jan 23]. Available from: https://www.nap.edu/catalog/6376
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87:222–8.
Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002;100:215–24.
Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. Δ9-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure. Invest Ophthalmol Vis Sci. 2018;59(15):5904–11.
Green K, Bigger JF, Kim K, Bowman K. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res. 1977;24:197–205.
Hingorani T, Gul W, ElSohly M, Repka MA, Majumdar S. Effect of ion-pairing on in vitro transcorneal permeability of a Δ9-tetrahydrocannabinol prodrug: potential in glaucoma therapy. J Pharm Sci. 2012;101:616–26.
Elsohly MA, Gul W, Repka MA, Majumdar S, inventors; ElSohly Laboratories Inc, assignee. Compositions containing delta-9-thc-amino acid esters and process of preparation. United States patent US 8,809,261. 2014 Aug 19.
Thumma S, Majumdar S, ElSohly MA, Gul W, Repka MA. Preformulation studies of a prodrug of Δ 9-tetrahydrocannabinol. AAPS PharmSciTech Sep 1. 2008;9(3):982–90.
Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993;37:435–56.
Kale SN, Deore SL. Emulsion micro emulsion and nano emulsion: A Review. 2016.
Sharma N, Bansal M, Visht S, Sharma P, Kulkarni G. Nanoemulsion: a new concept of delivery system. Chron Young Sci. 2010;5.
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2:47–64.
Kumari B. Ocular drug delivery system: approaches to improve ocular bioavailability. GSC Biol Pharm Sci. 2019;6:001–10.
Youssef A, Dudhipala N, Majumdar S. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics Jun. 2020;12(6):572.
Janga KY, Tatke A, Dudhipala N, Balguri SP, Ibrahim MM, Maria DN, Jablonski MM, Majumdar S. Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery. J Pharmacol Exp Ther Sep 1. 2019;370(3):814–22.
Inactive Ingredient Search for Approved Drug Products [Internet]. [cited 2020 Jan 28]. Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browseByLetter.page&Letter=P
Abismaı̈l B, Canselier JP, Wilhelm AM, Delmas H, Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason Sonochem. 1999;6:75–83.
Delmas T, Piraux H, Couffin A-C, Texier I, Vinet F, Poulin P, et al. How to prepare and stabilize very small nanoemulsions. Langmuir American Chemical Society. 2011;27:1683–92.
Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnology. 2011;02:626–39.
Tatke A, Dudhipala N, Janga KY, Balguri SP, Avula B, Jablonski MM, Majumdar S. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials. 2019;9(1):33.
Guan Y, Wu J, Zhong Q. Eugenol improves physical and chemical stabilities of nanoemulsions loaded with β-carotene. Food Chem. 2016;194:787–96.
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010;29:596–609.
Ban J, Zhang Y, Huang X, Deng G, Hou D, Chen Y, et al. Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone. Int J Nanomedicine. 2017;12:1329–39.
Chanana GD, Sheth BB. Particle size reduction of emulsions by formulation design-II: effect of oil and surfactant concentration. PDA J Pharm Sci Technol. 1995;49:71–6.
Pepi I, Lovri J, Filipovi J. Polymeric micelles in ocular drug delivery: rationale, strategies and challenges. :14.
Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004;78:639–51.
Lim KS, Nau CB, O’Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover study. Ophthalmology. 2008;115:790–5.